vs
Side-by-side financial comparison of Fiverr International Ltd. (FVRR) and Pacira BioSciences, Inc. (PCRX). Click either name above to swap in a different company.
Fiverr International Ltd. is the larger business by last-quarter revenue ($287.8M vs $177.4M, roughly 1.6× Pacira BioSciences, Inc.). Fiverr International Ltd. runs the higher net margin — 1.9% vs 1.6%, a 0.2% gap on every dollar of revenue. Over the past eight quarters, Fiverr International Ltd.'s revenue compounded faster (29.5% CAGR vs -0.2%).
Fiverr International Ltd. operates a global online freelance services marketplace connecting businesses and independent creators across over 160 countries. It offers services covering digital marketing, graphic design, programming, writing, video editing, and other professional fields, catering to SMEs, startups, and enterprise clients needing flexible on-demand talent solutions.
Pacira BioSciences, Inc. is a specialty pharmaceutical company focused on developing and commercializing non-opioid pain management solutions. Its core product line targets post-surgical pain relief for patients, serving hospitals, ambulatory surgery centers and other healthcare providers primarily in the U.S., with ongoing expansion efforts in select international markets.
FVRR vs PCRX — Head-to-Head
Income Statement — Q3 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $287.8M | $177.4M |
| Net Profit | $5.4M | $2.9M |
| Gross Margin | 82.5% | — |
| Operating Margin | -3.5% | 3.9% |
| Net Margin | 1.9% | 1.6% |
| Revenue YoY | — | 5.0% |
| Net Profit YoY | — | — |
| EPS (diluted) | — | $0.07 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $177.4M | ||
| Q4 25 | — | $196.9M | ||
| Q3 25 | $287.8M | $179.5M | ||
| Q2 25 | $188.2M | $181.1M | ||
| Q1 25 | $93.5M | $168.9M | ||
| Q4 24 | — | $187.3M | ||
| Q3 24 | $269.9M | $168.6M | ||
| Q2 24 | $177.3M | $178.0M |
| Q1 26 | — | $2.9M | ||
| Q4 25 | — | — | ||
| Q3 25 | $5.4M | $5.4M | ||
| Q2 25 | $4.1M | $-4.8M | ||
| Q1 25 | $788.0K | $4.8M | ||
| Q4 24 | — | — | ||
| Q3 24 | $-1.0M | $-143.5M | ||
| Q2 24 | $-4.0M | $18.9M |
| Q1 26 | — | — | ||
| Q4 25 | — | 79.5% | ||
| Q3 25 | 82.5% | 80.9% | ||
| Q2 25 | 83.3% | 77.4% | ||
| Q1 25 | 83.5% | 79.7% | ||
| Q4 24 | — | 78.7% | ||
| Q3 24 | 82.8% | 76.9% | ||
| Q2 24 | 82.4% | 75.1% |
| Q1 26 | — | 3.9% | ||
| Q4 25 | — | 1.2% | ||
| Q3 25 | -3.5% | 3.5% | ||
| Q2 25 | -3.4% | 4.7% | ||
| Q1 25 | -4.4% | 1.2% | ||
| Q4 24 | — | 13.2% | ||
| Q3 24 | -5.0% | -82.8% | ||
| Q2 24 | -6.3% | 15.9% |
| Q1 26 | — | 1.6% | ||
| Q4 25 | — | — | ||
| Q3 25 | 1.9% | 3.0% | ||
| Q2 25 | 2.2% | -2.7% | ||
| Q1 25 | 0.8% | 2.8% | ||
| Q4 24 | — | — | ||
| Q3 24 | -0.4% | -85.1% | ||
| Q2 24 | -2.3% | 10.6% |
| Q1 26 | — | $0.07 | ||
| Q4 25 | — | $0.05 | ||
| Q3 25 | — | $0.12 | ||
| Q2 25 | — | $-0.11 | ||
| Q1 25 | — | $0.10 | ||
| Q4 24 | — | $0.38 | ||
| Q3 24 | — | $-3.11 | ||
| Q2 24 | — | $0.39 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $133.5M | $144.3M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $362.6M | $653.9M |
| Total Assets | $1.1B | $1.2B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $144.3M | ||
| Q4 25 | — | $238.4M | ||
| Q3 25 | $133.5M | $246.3M | ||
| Q2 25 | $578.4M | $445.9M | ||
| Q1 25 | $133.5M | $493.6M | ||
| Q4 24 | — | $484.6M | ||
| Q3 24 | $183.7M | $453.8M | ||
| Q2 24 | $183.7M | $404.2M |
| Q1 26 | — | — | ||
| Q4 25 | — | $372.2M | ||
| Q3 25 | — | $376.7M | ||
| Q2 25 | — | $580.5M | ||
| Q1 25 | — | $583.4M | ||
| Q4 24 | — | $585.3M | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
| Q1 26 | — | $653.9M | ||
| Q4 25 | — | $693.1M | ||
| Q3 25 | $362.6M | $727.2M | ||
| Q2 25 | $404.9M | $757.8M | ||
| Q1 25 | $362.6M | $798.5M | ||
| Q4 24 | — | $778.3M | ||
| Q3 24 | $355.8M | $749.6M | ||
| Q2 24 | $355.8M | $879.3M |
| Q1 26 | — | $1.2B | ||
| Q4 25 | — | $1.3B | ||
| Q3 25 | $1.1B | $1.3B | ||
| Q2 25 | $1.1B | $1.5B | ||
| Q1 25 | $1.1B | $1.6B | ||
| Q4 24 | — | $1.6B | ||
| Q3 24 | $1.0B | $1.5B | ||
| Q2 24 | $1.0B | $1.6B |
| Q1 26 | — | — | ||
| Q4 25 | — | 0.54× | ||
| Q3 25 | — | 0.52× | ||
| Q2 25 | — | 0.77× | ||
| Q1 25 | — | 0.73× | ||
| Q4 24 | — | 0.75× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $53.0M | — |
| Free Cash FlowOCF − Capex | $52.1M | — |
| FCF MarginFCF / Revenue | 18.1% | — |
| Capex IntensityCapex / Revenue | 0.3% | — |
| Cash ConversionOCF / Net Profit | 9.81× | — |
| TTM Free Cash FlowTrailing 4 quarters | $124.9M | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | — | $43.7M | ||
| Q3 25 | $53.0M | $60.8M | ||
| Q2 25 | $42.2M | $12.0M | ||
| Q1 25 | $21.2M | $35.5M | ||
| Q4 24 | — | $33.1M | ||
| Q3 24 | $10.9M | $53.9M | ||
| Q2 24 | $32.2M | $53.2M |
| Q1 26 | — | — | ||
| Q4 25 | — | $43.5M | ||
| Q3 25 | $52.1M | $57.0M | ||
| Q2 25 | $41.5M | $9.3M | ||
| Q1 25 | $20.8M | $26.9M | ||
| Q4 24 | — | $31.0M | ||
| Q3 24 | $10.6M | $49.8M | ||
| Q2 24 | $31.5M | $51.6M |
| Q1 26 | — | — | ||
| Q4 25 | — | 22.1% | ||
| Q3 25 | 18.1% | 31.7% | ||
| Q2 25 | 22.0% | 5.1% | ||
| Q1 25 | 22.3% | 15.9% | ||
| Q4 24 | — | 16.6% | ||
| Q3 24 | 3.9% | 29.6% | ||
| Q2 24 | 17.8% | 29.0% |
| Q1 26 | — | — | ||
| Q4 25 | — | 0.1% | ||
| Q3 25 | 0.3% | 2.2% | ||
| Q2 25 | 0.4% | 1.5% | ||
| Q1 25 | 0.4% | 5.1% | ||
| Q4 24 | — | 1.1% | ||
| Q3 24 | 0.1% | 2.4% | ||
| Q2 24 | 0.4% | 0.9% |
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | 9.81× | 11.20× | ||
| Q2 25 | 10.40× | — | ||
| Q1 25 | 26.90× | 7.37× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | 2.82× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
FVRR
Segment breakdown not available.
PCRX
| EXPAREL | $143.3M | 81% |
| ZILRETTA | $26.8M | 15% |
| iovera° | $6.2M | 3% |
| Bupivacaine liposome injectable suspension | $1.2M | 1% |
